Clinical Trial

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

Study acronym: HMBeacon
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-13
notable Trial sites expanded: 1 -> 4 locations 2026-08-13
Trial Details
NCT Number NCT07575308
Lead Sponsor Alnylam Pharmaceuticals
Conditions Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
Enrollment 24 participants
Start Date 2026-07-30
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-11-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-12